A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
Condition: Pancreatic Cancer Interventions: Drug: Exenatide; Drug: Non-GLP-1 RA based glucose lowering drugs Sponsor: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Byetta | Cancer | Cancer & Oncology | Diabetes | Diabetes Type 2 | Endocrinology | Pancreas | Pancreatic Cancer | Research | Study